BACKGROUND AND PURPOSE: Growth of subependymal giant cell tumor and
subependymal nodules has not been well-characterized. The purpose of this study was to …

This study investigated whether subependymal giant cell tumors (SGCT) grow after the
second decade in patients with tuberous sclerosis complex (TSC). In this retrospective …

OBJECTIVES Intraventricular astrocytomas (subependymal giant cell astrocytomas) of
tuberous sclerosis have a poor prognosis due to the obstruction of CSF flow. The aim of this …

We present 19 patients with tuberous sclerosis complex and subependymal giant cell
astrocytoma. The mean age at the time of tumor diagnosis was 9.4 years (range, 1.5 to 21 …

Object Subependymal giant cell astrocytomas (SEGAs) are a common manifestation of
tuberous sclerosis (TS). These evolving tumors have a propensity to cause obstructive …

Purpose The purpose of this study was to estimate the association among the presence of
subependymal nodules (SENs), subependymal giant cell tumours (SGCTs) and gene …

Objectives: To describe the clinical presentations, radiologic features, and postoperative
outcomes of a clinic-based population of patients with subependymal giant cell tumors …

OBJECTIVE: A small percentage of tuberous sclerosis patients will develop a subependymal
giant-cell astrocytoma. Given the morbidity and mortality when such a lesion is left …

Background Subependymal giant cell astrocytoma is a brain tumor associated with tuberous
sclerosis complex. There are two treatment options for subependymal giant cell …

Subependymal giant cell tumors (SGCTs) are observed in 5–20% of patients with tuberous
sclerosis complex (TSC) but account for~ 25% of neurological morbidity. The authors report …